TOKYO, Jun 15 (Pulse News Wire) – Kitazato Corporation (368A.T) resolved at its board meeting held on June 15, 2026 to establish a joint venture with Repro Lifesciences LLP in India aimed at enhancing regulatory compliance and market understanding. The joint venture, named Kitazato India Private Limited (tentative), will focus on managing product registrations, market understanding, and customer support services related to infertility treatment products.
The joint venture's capital will amount to 5,000,000 Indian Rupees (¥8.5 million). Kitazato Corporation will hold 51% shares of the joint venture, while Repro Lifesciences LLP will contribute 49%. The establishment of the joint venture is scheduled for July 2026, with operations set to commence in October 2026.
Repro Lifesciences LLP was established on July 2, 2024, with a capital of 2,000,000 Indian Rupees (¥3.4 million). The joint venture will strengthen Kitazato’s presence in the Indian market through enhanced promotional and technical support. The company expects the impact on its fiscal year 2027 performance to be minor.
Any significant developments will be promptly disclosed.
🟡 Confidence: Standard AI-translated content.